BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 27248570)

  • 21. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.
    Ikegami T; Narayanan K; Won S; Kamitani W; Peters CJ; Makino S
    PLoS Pathog; 2009 Feb; 5(2):e1000287. PubMed ID: 19197350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The NSs Protein Encoded by the Virulent Strain of Rift Valley Fever Virus Targets the Expression of Abl2 and the Actin Cytoskeleton of the Host, Affecting Cell Mobility, Cell Shape, and Cell-Cell Adhesion.
    Bamia A; Marcato V; Boissière M; Mansuroglu Z; Tamietti C; Romani M; Simon D; Tian G; Niedergang F; Panthier JJ; Flamand M; Souès S; Bonnefoy E
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33087469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A shared transcription termination signal on negative and ambisense RNA genome segments of Rift Valley fever, sandfly fever Sicilian, and Toscana viruses.
    Albariño CG; Bird BH; Nichol ST
    J Virol; 2007 May; 81(10):5246-56. PubMed ID: 17329326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice.
    Vialat P; Billecocq A; Kohl A; Bouloy M
    J Virol; 2000 Feb; 74(3):1538-43. PubMed ID: 10627566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy of two next-generation Rift Valley fever vaccines.
    Kortekaas J; Oreshkova N; van Keulen L; Kant J; Bosch BJ; Bouloy M; Moulin V; Goovaerts D; Moormann RJ
    Vaccine; 2014 Sep; 32(39):4901-8. PubMed ID: 25050973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep.
    Bird BH; Maartens LH; Campbell S; Erasmus BJ; Erickson BR; Dodd KA; Spiropoulou CF; Cannon D; Drew CP; Knust B; McElroy AK; Khristova ML; Albariño CG; Nichol ST
    J Virol; 2011 Dec; 85(24):12901-9. PubMed ID: 21976656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of monoclonal antibodies to Rift Valley Fever Virus and their application in antigen detection and indirect immunofluorescence.
    Mroz C; Schmidt KM; Reiche S; Groschup MH; Eiden M
    J Immunol Methods; 2018 Sep; 460():36-44. PubMed ID: 29894749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment.
    Muller R; Saluzzo JF; Lopez N; Dreier T; Turell M; Smith J; Bouloy M
    Am J Trop Med Hyg; 1995 Oct; 53(4):405-11. PubMed ID: 7485695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever.
    Lihoradova O; Ikegami T
    Expert Rev Vaccines; 2012 Nov; 11(11):1283-5. PubMed ID: 23249225
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12ΔNSm21/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania.
    Nyundo S; Adamson E; Rowland J; Palermo PM; Matiko M; Bettinger GE; Wambura P; Morrill JC; Watts DM
    Onderstepoort J Vet Res; 2019 Jan; 86(1):e1-e8. PubMed ID: 30843406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals.
    Bird BH; Albariño CG; Hartman AL; Erickson BR; Ksiazek TG; Nichol ST
    J Virol; 2008 Mar; 82(6):2681-91. PubMed ID: 18199647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12ΔNSm21/384 vaccine candidate for sheep, goats and calves.
    Boumart Z; Daouam S; Bamouh Z; Jazouli M; Tadlaoui KO; Dungu B; Bettinger G; Watts DM; Elharrak M
    Vaccine; 2019 Mar; 37(12):1642-1650. PubMed ID: 30773401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
    Ikegami T
    Expert Rev Vaccines; 2017 Jun; 16(6):601-611. PubMed ID: 28425834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional analysis of Rift Valley fever virus NSs encoding a partial truncation.
    Head JA; Kalveram B; Ikegami T
    PLoS One; 2012; 7(9):e45730. PubMed ID: 23029207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Change P82L in the Rift Valley Fever Virus NSs Protein Confers Attenuation in Mice.
    Borrego B; Moreno S; de la Losa N; Weber F; Brun A
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33805122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation of adjacent cysteine residues in the NSs protein of Rift Valley fever virus results in loss of virulence in mice.
    Monteiro GER; Jansen van Vuren P; Wichgers Schreur PJ; Odendaal L; Clift SJ; Kortekaas J; Paweska JT
    Virus Res; 2018 Apr; 249():31-44. PubMed ID: 29530722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus.
    Fernandez JC; Billecocq A; Durand JP; Cêtre-Sossah C; Cardinale E; Marianneau P; Pépin M; Tordo N; Bouloy M
    Clin Vaccine Immunol; 2012 Jan; 19(1):5-10. PubMed ID: 22072723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep.
    Weingartl HM; Nfon CK; Zhang S; Marszal P; Wilson WC; Morrill JC; Bettinger GE; Peters CJ
    Vaccine; 2014 Apr; 32(20):2345-9. PubMed ID: 24462482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model.
    Ikegami T; Balogh A; Nishiyama S; Lokugamage N; Saito TB; Morrill JC; Shivanna V; Indran SV; Zhang L; Smith JK; Perez D; Juelich TL; Morozov I; Wilson WC; Freiberg AN; Richt JA
    PLoS One; 2017; 12(12):e0189250. PubMed ID: 29267298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a novel, single-cycle replicable rift valley Fever vaccine.
    Murakami S; Terasaki K; Ramirez SI; Morrill JC; Makino S
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2746. PubMed ID: 24651859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.